Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | HTR5A | P47898 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13879527 | 0.80 | ALDH1A1 (0.57) | ARKMT2AMGLLPOLBALDH1A1 | |
| SCHEMBL5740339 | 0.79 | KMT2A (0.72) | ARKMT2APOLBALDH1A1GAA | |
| SCHEMBL5740144 | 0.79 | LMNA (0.54) | ARKMT2AMGLLALDH1A1KDM4E | |
| SCHEMBL5738288 | 0.78 | AR (0.62) | ARKMT2APOLBALDH1A1KDM4E | |
| SCHEMBL13879410 | 0.78 | KDM4E (0.57) | ARKMT2AMGLLPOLBALDH1A1 | |
| SCHEMBL13879486 | 0.76 | ALDH1A1 (0.56) | ARKMT2AMGLLPOLBALDH1A1 | |
| SCHEMBL5740800 | 0.75 | KMT2A (0.66) | ARKMT2AALDH1A1KDM4EGAA | |
| SCHEMBL13879455 | 0.74 | KDM4E (0.56) | ARKMT2AMGLLPOLBALDH1A1 | |
| SCHEMBL6095733 | 0.69 | AR (1.00) | ARKMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL13879374 | 0.69 | AR (0.48) | ARKMT2APOLBALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1244670-B1 | HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USING SAME | MGI GP INC (US) | 2006-03-08 | — | — | EP | claimed |
| US-20020058685-A1 | Hydantoin derivative compounds, pharmace utical compositions, and methods of using same | GLIAMED, INC. | 2002-05-16 | — | — | US | claimed |
| EP-1244670-B1 | HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USING SAME | MGI GP INC (US) | 2006-03-08 | — | — | EP | disclosed |
| US-6974823-B2 | Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same | GPI NIL HOLDINDGS, INC. (US) | 2005-12-13 | — | — | US | disclosed |
| US-20030203890-A1 | Method for treating nerve injury caused as a result of surgery | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-10-30 | — | — | US | disclosed |
| US-20020058685-A1 | Hydantoin derivative compounds, pharmace utical compositions, and methods of using same | GLIAMED, INC. | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203890-A1 | Method for treating nerve injury caused as a result of surgery | NGF, BDNF, GAP43 | AR 447/4885KMT2A 4086/4885MGLL 2735/4885 |
| US-20020058685-A1 | Hydantoin derivative compounds, pharmace utical compositions, and methods of using same | HNMT, HAAO, HTR3E | AR 2055/4885KMT2A 3409/4885MGLL 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.